Okyo Pharma reports results from Phase 2a trial of urcosimod

OKYO Pharma (OKYO) announced new positive findings from an exploratory analysis of patient-reported outcomes in its recently completed Phase 2a trial of urcosimod for the treatment of NCP. This new quality-of-life, or QoL, data will be presented at the Association for Research in Vision and Ophthalmology, or ARVO, 2026 Annual Meeting. The presentation, titled: “First-in-Human Study of Urcosimod to Treat Neuropathic Corneal Pain, or NCP, Shows Clinically Meaningful Pain Reduction and Quality-of-Life Improvement in NCP Patients” will detail the Phase 2a clinical trial results, including reductions in pain as measured by the VAS, improvements in patient-reported QoL measures, as well as signals suggesting potential restoration of corneal nerve structure in NCP patients. This event represents a key opportunity to share these new findings with global eye and vision researchers, clinicians, and industry leaders. In this Phase 2, randomized, double-masked, placebo-controlled study, patients with NCP received either 0.05% urcosimod or placebo in the Intent-to-Treat, or ITT, population. After 12 weeks of treatment, patients receiving urcosimod demonstrated greater improvements across key aspects of emotional well-being and quality of life compared to placebo. These measures were assessed on a 0-10 scale. Notable improvements included: Enjoying life/relationships with other people: mean change from baseline of -4.5 for urcosimod vs. 0 for placebo.